Apolipoprotein A1 gene polymorphisms and risk of early coronary disease

Cardiology

Volumn 90, Issue 3, 1998, Pages 231-235

  Reguero, Julián R ^a   Cubero, Gustavo Iglesias ^a   Batalla, Alberto ^a   Alvarez, Victoria ^a   Hevia, Sergio ^a   Cortina, Arturo ^a   Coto, Eliecer ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Apolipoprotein A1; Cardiovascular risk factors; Coronary artery disease; DNA polymorphisms

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TOBACCO; UNSTABLE ANGINA PECTORIS;

ADULT; ALLELES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CORONARY DISEASE; DNA; DNA PROBES; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 0032414846     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006849     Document Type: Article

References (21)

1. Slack J, Evans KA: The increased risk of death from ischaemic heart disease in first-degree relatives of 121 men and 96 women with ischaemic heart disease. J Med Genet 1966;3:239-259.
2. Fuster V, Badimon L, Badimon JJ, Chesebro HJ: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-318.
3. Berg K: Twin studies of coronary heart disease and its risk factors. Acta Genet Med Gemellol (Roma) 1984;33:349-361.
4. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: A metaanalysis and review of the literature. Ann Intern Med 1993;118:956-963.
5. Boushey CJ: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
6. Welty FK, Mittleman MA, Wilson PWF, Sutherland PA, Matheney TH, Lipinska I, Muller JE, Levy D, Tofler GH: Hypobeta lipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham Offspring population. Circulation 1997;95:825-830.
7. Steinmetz J, Boerwinkle E, Gueguen S, Visvikis J, Henny J, Siest G: Multivariate genetic analysis of high density lipoprotein. Atherosclerosis 1992;92:219-227.
8. Blanguero J, Willians-Blanguero S, Mahaney MC: Multivariate genetic analysis of apoA1 concentrations and HDL subfractions: Evidence for major locus pleitropy. Genet Epidemiol 1993;10:617-622.
9. Talmud PJ, Ye S, Humphries SE, and the EARS Group: Polymorphisms in the promoter region of the apolipoprotein AI gene associated with differences in apolipoproteins AI levels: The European atherosclerosis research study. Genet Epidemiol 1994;11:265-280.
10. Wang XL, Badenhop R, Humphrey K, Wilcken DEL: C to T and G to A transitions are responsible for loss of a MspI restriction site in the 5′-region of the human apolipoprotein AI gene. Hum Genet 1995;95:473-475.
11. Wang XL, Liu SX, McCredie RM, Wilcken DEL: Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996;98:372-377.
12. WHO MONICA Project: MONICA Manual, revised edition. Geneva, Cardiovascular Diseases Unit, WHO, 1990.
13. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
14. Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgellés MF, Menendez MJ, Carracedo C, López-Larrea C, Coto E: Factor V Leiden (R506Q) and risk of venous thromboembolism: A case-control study based on the Spanish population. Clin Genet 1997;52:206-210.
15. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964;ii:177-180.
16. Bai H, Saku K, Liu R, Jimi S, Arakawa K: Analysis of a new polymorphism in the human apolipoprotein AI gene: Association with serum lipoproteins levels and coronary heart disease. J Cardiol 1996;28:207-212.
17. Assmann G, von Eckardstein A, Funke H: High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations (review). Circulation 1993;87(suppl III):III28-III34.
18. Pagani F, Giudici GA, Baralle FE, Vergani C: Association of a polymorphism in the apo AI gene promoter with hyperalphalipoproteinemia. Eur J Epidemiol 1992;8(suppl 1):54-58.
19. Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE: Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: Detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet 1992;88:439-446.
20. Hong SH, Park WH, Lee CC, Song JH, Kim JK: Association between genetic variation of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem 1997;43:13-17.
21. Lopez-Miranda J, Ordovás JM, Espino A, Marin C, Salas J, Lopez Segura F, Jimenez Perezperez J, Perez-Jimenez F: Influence of mutation in human apolipoprotein A-1 gene promoter on plasma LDL cholesterol response to dietary fat. Lancet 1994;343:1246-1249.